WB | 1/500-1/1000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 咨询技术 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 1/10000 | Human,Mouse,Rat |
Aliases | IL17RC; Interleukin-17 receptor C; IL-17 receptor C; IL-17RC; Interleukin-17 receptor homolog; IL17Rhom; Interleukin-17 receptor-like protein; IL-17RL; ZcytoR14 |
Entrez GeneID | 84818 |
WB Predicted band size | Calculated MW: 86 kDa; Observed MW: 70 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | The antiserum was produced against synthesized peptide derived from human IL17RC. AA range:721-770 |
Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于IL-17 Receptor C抗体的3篇参考文献示例(注:以下内容为模拟生成,实际文献需通过数据库检索确认):
1. **文献名称**:*"A neutralizing antibody targeting IL-17 Receptor C ameliorates psoriasis-like skin inflammation in mice*"
**作者**:Wang Y, et al.
**摘要**:研究开发了一种靶向IL-17RC的单克隆抗体,在小鼠银屑病模型中显著抑制Th17细胞介导的皮肤炎症,证明其通过阻断IL-17A/IL-17F与受体的结合发挥作用。
2. **文献名称**:*"Structural basis of IL-17 receptor C recognition by a therapeutic antibody for autoimmune diseases*"
**作者**:Chen X, et al.
**摘要**:通过冷冻电镜解析了抗IL-17RC抗体与受体复合物的结构,揭示了抗体特异性结合受体胞外域的机制,为优化治疗性抗体设计提供了依据。
3. **文献名称**:*"Targeting IL-17RC in experimental colitis: antibody blockade reduces intestinal inflammation and fibrosis*"
**作者**:Lee S, et al.
**摘要**:在结肠炎模型中,抗IL-17RC抗体通过抑制IL-17信号通路,显著减轻肠道炎症反应和纤维化,提示其治疗炎症性肠病的潜力。
4. **文献名称**:*"IL-17 Receptor C as a novel therapeutic target in rheumatoid arthritis: preclinical efficacy of a humanized antibody*"
**作者**:Garcia-Hernandez A, et al.
**摘要**:研究报道了一种人源化抗IL-17RC抗体在类风湿关节炎动物模型中的疗效,显示其可减少关节破坏和促炎细胞因子产生,支持其进入临床试验。
建议通过PubMed、Google Scholar等平台,以关键词“IL-17 Receptor C antibody”“anti-IL17RC therapeutic”检索最新文献以获取准确信息。
The IL-17 receptor C (IL-17RC) is a key component of the heterodimeric receptor complex (IL-17RA/RC) that mediates signaling for IL-17A and IL-17F, cytokines central to inflammatory and autoimmune responses. IL-17RC, structurally characterized by extracellular fibronectin III-like domains and a cytoplasmic SEFIR domain, binds IL-17 ligands with high affinity, enabling recruitment of adaptors like Act1 to trigger downstream pro-inflammatory pathways (NF-κB, MAPK). Dysregulated IL-17 signaling is implicated in psoriasis, rheumatoid arthritis, and inflammatory bowel disease.
IL-17RC-targeting antibodies, such as brodalumab, block IL-17A/F binding or receptor activation, suppressing pathogenic inflammation. Unlike antibodies targeting IL-17A (e.g., secukinumab) or IL-17RA, IL-17RC-specific agents may offer selective modulation, potentially reducing off-target effects. Preclinical studies demonstrate efficacy in reducing Th17-driven inflammation in skin and joint models. Clinical trials in psoriasis showed significant improvement, though safety concerns (e.g., candidiasis risk due to IL-17’s role in mucosal immunity) necessitate careful evaluation. Research continues to explore IL-17RC's role in cancer and fibrosis, expanding therapeutic potential. These antibodies represent a precision strategy to disrupt IL-17 signaling while preserving redundant immune pathways.
×